Literature DB >> 33423415

Teledermatology application use in the COVID-19 era.

Kayd J Pulsipher, Colby L Presley, Chandler W Rundle, Hope R Rietcheck, Michelle Millitelo, Robert P Dellavalle1.   

Abstract

Owing to the COVID-19 outbreak, the use of telemedicine applications has increased throughout the United States. Using an algorithm to analyze mobile application rankings, we were able to examine how applications with telemedicine services have increased in prevalence and rank pre- and post- COVID-19. Telemedicine apps saw an increase of 210.92 ranked positions on average. Within US telehealth, skin conditions have become the fifth most common diagnosis. Widespread use of teledermatology has been well-accepted. Dermatologists and patients report high satisfaction using teledermatology during COVID-19 and intend to continue using these services in the future. COVID-19 has assisted in reducing physician concerns previously preventing some dermatologists from utilizing teledermatology in their services. Additionally, the geographical and socioeconomic barriers preventing some patients from receiving dermatologic care have been minimized through the use of teledermatology. Addressing these obstacles for dermatologic care improves healthcare equity.

Entities:  

Year:  2020        PMID: 33423415

Source DB:  PubMed          Journal:  Dermatol Online J        ISSN: 1087-2108


  3 in total

Review 1.  Social Media and Ethical Challenges for the Dermatologist.

Authors:  Michelle Militello; Ronald A Yang; Jaclyn B Anderson; Mindy D Szeto; Colby L Presley; Melissa R Laughter
Journal:  Curr Dermatol Rep       Date:  2021-09-13

Review 2.  Teledermatology During COVID-19: An Updated Review.

Authors:  Morgan A Farr; Madeleine Duvic; Tejas P Joshi
Journal:  Am J Clin Dermatol       Date:  2021-04-09       Impact factor: 6.233

Review 3.  mHealth and telemedicine utility in the monitoring of allergic diseases.

Authors:  Violeta Kvedarienė; Paulina Burzdikaitė; Inga Česnavičiūtė
Journal:  Front Allergy       Date:  2022-09-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.